Abstract
Major advances have been made in our understanding of CNS tumors, especially glioma, however, the survival of patients with malignant glioma remains poor. While radiation and chemotherapy have increased overall survival, glioblastoma multiforme (GBM) still has one of the worst 5-year survival rates of all human cancers. Here, in this chapter, the authors review the abrogation of the immune system in the tumor setting, revealing many plausible targets for therapy and the current immunotherapy treatment strategies employed. Notably, glioma has also been characterized as a subset of primary spinal cord tumor and current treatment recommendations are outlined here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdel-Wahab M et al (2006) Spinal cord gliomas: a multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys 64:1060–1071. https://doi.org/10.1016/j.ijrobp.2005.09.038
Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr (2012) Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 35:385–389. https://doi.org/10.1097/CJI.0b013e3182562d59
Alterman RL, Stanley ER (1994) Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol 21:177–188. https://doi.org/10.1007/bf02815350
Arlauckas SP et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9. https://doi.org/10.1126/scitranslmed.aal3604
Avril T et al (2010) Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 225:22–33. https://doi.org/10.1016/j.jneuroim.2010.04.003
Babic I et al (2018) Pritumumab, the first therapeutic antibody for glioma patients. Hum Antibodies 26:95–101. https://doi.org/10.3233/hab-170326
Badie B, Schartner J, Prabakaran S, Paul J, Vorpahl J (2001) Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 120:19–24. https://doi.org/10.1016/s0165-5728(01)00361-7
Badie B, Schartner JM (2000) Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46:957–961; discussion 961–952. https://doi.org/10.1097/00006123-200004000-00035
Belcaid Z et al (2014) Focal radiation therapy combined with 4–1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE 9:e101764–e101764. https://doi.org/10.1371/journal.pone.0101764
Berghoff AS et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:1064–1075. https://doi.org/10.1093/neuonc/nou307
Braun DP, Penn RD, Flannery AM, Harris JE (1982) Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 10:203–209
Brown CE et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561–2569. https://doi.org/10.1056/NEJMoa1610497
Brown NF et al (2020) A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. BMC Cancer 20:198. https://doi.org/10.1186/s12885-020-6624-y
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity 27:111–122. https://doi.org/10.1016/j.immuni.2007.05.016
Chamberlain MC, Tredway TL (2011) Adult primary intradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 11:320–328. https://doi.org/10.1007/s11910-011-0190-2
Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV (2018) The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology 223:101–111. https://doi.org/10.1016/j.imbio.2017.10.005
Clarke JL et al (2011) Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 13:1118–1124. https://doi.org/10.1093/neuonc/nor110
Cloughesy TF et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477–486. https://doi.org/10.1038/s41591-018-0337-7
Corradini S, Hadi I, Hankel V, Ertl L, Ganswindt U, Belka C, Niyazi M (2016) Radiotherapy of spinal cord gliomas: a retrospective mono-institutional analysis. Strahlenther Onkol 192:139–145. https://doi.org/10.1007/s00066-015-0917-0
Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 14:584–595. https://doi.org/10.1093/neuonc/nos014
de Martin R et al (1987) Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. Embo j 6:3673–3677
DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369–382. https://doi.org/10.1038/s41577-019-0127-6
Di Tomaso T et al (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16:800–813. https://doi.org/10.1158/1078-0432.Ccr-09-2730
Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, Weller M (2011) APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 13(2):155–64. Epub 2010 Dec 22. PMID: 21183510, PMCID: PMC3064626. https://doi.org/10.1093/neuonc/noq176
Fecci PE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. https://doi.org/10.1158/0008-5472.Can-05-3773
Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158–2167. https://doi.org/10.1158/1078-0432.Ccr-06-2070
Feng K et al (2018) Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 9:838–847. https://doi.org/10.1007/s13238-017-0440-4
Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL (2019) Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19:568–586. https://doi.org/10.1038/s41568-019-0183-z
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O’Garra A (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444–3451
Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ, Weller M (2015) Transforming growth factor-beta pathway activity in glioblastoma. Oncotarget 6:5963–5977. https://doi.org/10.18632/oncotarget.3467
Gallego Perez-Larraya J, Hildebrand J (2014) Brain metastases. Handb Clin Neurol 121:1143–1157. https://doi.org/10.1016/b978-0-7020-4088-7.00077-8
Gately CL et al (1984) In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol 133:3387–3395
Genoud V et al (2018) Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology 7:e1501137. https://doi.org/10.1080/2162402x.2018.1501137
Gerosa MA, Olivi A, Rosenblum ML, Semenzato GP, Pezzutto A (1982) Impaired immunocompetence in patients with malignant gliomas: the possible role of Tg-lymphocyte subpopulations. Neurosurgery 10:571–573. https://doi.org/10.1227/00006123-198205000-00004
Glassy MC, Hagiwara H (2009) Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum Antibodies 18:127–137. https://doi.org/10.3233/hab-2009-0209
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23–35. https://doi.org/10.1038/nri978
Grimm S, Chamberlain MC (2009) Adult primary spinal cord tumors. Expert Rev Neurother 9:1487–1495. https://doi.org/10.1586/ern.09.101
Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:10024–10028. https://doi.org/10.1073/pnas.86.24.10024
Gutmann DH (2015) Microglia in the tumor microenvironment: taking their TOLL on glioma biology. Neuro Oncol 17:171–173. https://doi.org/10.1093/neuonc/nou346
Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27. https://doi.org/10.1038/nn.4185
Heczey A, Louis CU (2013) Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med 16:287–294
Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331
Held-Feindt J et al (2010) CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res 316:1553–1566. https://doi.org/10.1016/j.yexcr.2010.02.018
Henson JW, Thornton AF, Louis DN (2000) Spinal cord astrocytoma: response to PCV chemotherapy. Neurology 54:518–520. https://doi.org/10.1212/wnl.54.2.518
Herrlinger U et al (1997) Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4:345–352
Hishii M et al. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37:1160–1166; discussion 1166–1167. https://doi.org/10.1227/00006123-199512000-00016
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466
Hutter G et al (2019) Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci 116:997. https://doi.org/10.1073/pnas.1721434116
Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L (2014) Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol 7:57. https://doi.org/10.1186/s13045-014-0057-5
Italiani P, Boraschi D (2014) From monocytes to M1/M2 macrophages: phenotypical versus functional differentiation. Front Immunol 5:514. https://doi.org/10.3389/fimmu.2014.00514
Jackson S, ElAli A, Virgintino D, Gilbert MR (2017) Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer’s disease. Neuro Oncol 19:1173–1182. https://doi.org/10.1093/neuonc/nox058
Ji J, Black KL, Yu JS (2010) Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 21:159–166. https://doi.org/10.1016/j.nec.2009.08.006
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12:1167–1174. https://doi.org/10.1038/nm1483
Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ (2017) 2016 updates to the WHO brain tumor classification system: what the radiologist needs to know. Radiographics 37:2164–2180. https://doi.org/10.1148/rg.2017170037
Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A (1997) A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386:181–186. https://doi.org/10.1038/386181a0
Kohanbash G et al (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res 73:6413–6423. https://doi.org/10.1158/0008-5472.Can-12-4124
Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216:15–24. https://doi.org/10.1002/path.2370
Kucheryavykh LY, Rivera-Pagán AF, Rolón-Reyes K, Skatchkov SN, Eaton MJ (2013) Abstract 1429: Role of monocyte chemotactic protein-1 (MCP-1) in the tumor microenvironment. Can Res 73:1429. https://doi.org/10.1158/1538-7445.AM2013-1429
Ladomersky E et al (2018) IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 24:2559–2573. https://doi.org/10.1158/1078-0432.Ccr-17-3573
Lamborn KR et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162–170. https://doi.org/10.1215/15228517-2007-062
Lee WH, Seo D, Lim SG, Suk K (2019) Reverse signaling of tumor necrosis factor superfamily proteins in macrophages and microglia: superfamily portrait in the neuroimmune interface. Front Immunol 10:262. https://doi.org/10.3389/fimmu.2019.00262
Lemke D et al (2012) Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 18:105–117. https://doi.org/10.1158/1078-0432.Ccr-11-0880
Li F et al (2018) Blocking the CD47-SIRPalpha axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology 7:e1391973. https://doi.org/10.1080/2162402x.2017.1391973
Liau LM et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124. https://doi.org/10.3171/jns.1999.90.6.1115
Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5
Litak J, Mazurek M, Grochowski C, Kamieniak P, Rolinski J (2019) PD-L1/PD-1 axis in glioblastoma multiforme. Int J Mol Sci 20. https://doi.org/10.3390/ijms20215347
Liu G, Black KL, Yu JS (2006) Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 5:233–247. https://doi.org/10.1586/14760584.5.2.233
Liu X et al (2018) Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep 24:2101–2111. https://doi.org/10.1016/j.celrep.2018.07.062
Liu F, Huang J, Liu X, Cheng Q, Luo C, Liu Z (2020) CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int 20:7. https://doi.org/10.1186/s12935-019-1085-6
Louveau A et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341. https://doi.org/10.1038/nature14432
Majeti R et al (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286–299. https://doi.org/10.1016/j.cell.2009.05.045
Mangogna A et al (2019) Prognostic implications of the complement protein C1q in gliomas. Front Immunol 10:2366. https://doi.org/10.3389/fimmu.2019.02366
McNeill KA (2016) Epidemiology of brain tumors. Neurol Clin 34:981–998. https://doi.org/10.1016/j.ncl.2016.06.014
Meza Guzman LG, Keating N, Nicholson SE (2020) Natural killer cells: tumor surveillance and signaling. Cancers (Basel) 12. https://doi.org/10.3390/cancers12040952
Michael K, Jian G, Walavan S, Jayson AN, Meic HS, Mark AM (2015) The genetic basis of intradural spinal tumors and its impact on clinical treatment. Neurosurgical Focus FOC 39:E3. https://doi.org/10.3171/2015.5.FOCUS15143
Milano MT, Johnson MD, Sul J, Mohile NA, Korones DN, Okunieff P, Walter KA (2010) Primary spinal cord glioma: a surveillance, epidemiology, and end results database study. J Neurooncol 98:83–92. https://doi.org/10.1007/s11060-009-0054-7
Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H (2013) Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 72:1031–1038; discussion 1038–1039. https://doi.org/10.1227/NEU.0b013e31828cf945
Mok S et al (2014) Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 74:153–161. https://doi.org/10.1158/0008-5472.Can-13-1816
Murakami T et al (2018) Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells. Anticancer Res 38:5049–5056. https://doi.org/10.21873/anticanres.12824
Nduom EK, Weller M, Heimberger AB (2015) Immunosuppressive mechanisms in glioblastoma. Neuro Oncol 17(Suppl 7):vii9–vii14. https://doi.org/10.1093/neuonc/nov151
Nitta T, Hishii M, Sato K, Okumura K (1994) Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649:122–128. https://doi.org/10.1016/0006-8993(94)91055-3
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49–61. https://doi.org/10.1016/j.immuni.2014.06.010
Ochs K et al (2013) Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol 265:106–116. https://doi.org/10.1016/j.jneuroim.2013.09.011
Ogunlade J, Wiginton JGt, Elia C, Odell T, Rao SC (2019) Primary spinal astrocytomas: a literature review. Cureus 11:e5247. https://doi.org/10.7759/cureus.5247
Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP (2000) Role of CD47 as a marker of self on red blood cells. Science 288:2051–2054. https://doi.org/10.1126/science.288.5473.2051
O'Rourke DM et al. (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9. https://doi.org/10.1126/scitranslmed.aaa0984
Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA (2006) NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 55:1122–1131. https://doi.org/10.1007/s00262-005-0089-3
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Parsa AT, Chi JH, Acosta FL Jr, Ames CP, McCormick PC (2005) Intramedullary spinal cord tumors: molecular insights and surgical innovation. Clin Neurosurg 52:76–84
Passive Immunotherapy (2005) In: Vohr HW (ed) Encyclopedic reference of immunotoxicology. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 493–494. https://doi.org/10.1007/3-540-27806-0_1129
Perry JR et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977
Phuphanich S et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. https://doi.org/10.1007/s00262-012-1319-0
Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, Weller M (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54:388–392. https://doi.org/10.1002/ana.10679
Platten M, Ochs K, Lemke D, Opitz C, Wick W (2014) Microenvironmental clues for glioma immunotherapy. Curr Neurol Neurosci Rep 14:440. https://doi.org/10.1007/s11910-014-0440-1
Polyzoidis S, Ashkan K (2014) DCVax(R)-L–developed by Northwest biotherapeutics. Hum Vaccin Immunother 10:3139–3145. https://doi.org/10.4161/hv.29276
Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH (2013) Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 73:303–308. https://doi.org/10.1002/ana.23813
Pyonteck SM et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264–1272. https://doi.org/10.1038/nm.3337
Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12:623–635. https://doi.org/10.1038/nri3265
Raychaudhuri B et al (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13:591–599. https://doi.org/10.1093/neuonc/nor042
Reardon DA et al (2020) Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin Cancer Res 26:1586–1594. https://doi.org/10.1158/1078-0432.Ccr-18-1140
Reardon DA et al. (2017) OS10.3 randomized phase 3 study evaluating the efficacy and safety of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: checkmate 143. Neuro-Oncology 19:iii21–iii21. https://doi.org/10.1093/neuonc/nox036.071
Roa W et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588. https://doi.org/10.1200/jco.2004.06.082
Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M (2007) Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 67:3540–3544. https://doi.org/10.1158/0008-5472.Can-06-4783
Ruella M, Kalos M (2014) Adoptive immunotherapy for cancer. Immunol Rev 257:14–38. https://doi.org/10.1111/imr.12136
Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472. https://doi.org/10.1016/j.ccell.2015.02.015
Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L (2011) Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol 49:402–406. https://doi.org/10.1016/j.molimm.2011.09.006
Sadeghzadeh M et al. (2020) Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci 117580. https://doi.org/10.1016/j.lfs.2020.117580
Saha D, Martuza RL, Rabkin SD (2017) Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32:253-267.e255. https://doi.org/10.1016/j.ccell.2017.07.006
Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. https://doi.org/10.1200/jco.2010.28.6963
Sampson JH et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324–333. https://doi.org/10.1093/neuonc/noq157
Sampson JH et al. (2016) A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. J Clin Oncol 34:TPS2079–TPS2079. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS2079
Santoni M et al (2020) Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in renal cell carcinoma. Curr Drug Targets 21:416–423. https://doi.org/10.2174/1389450120666191017113051
Sarkar S et al (2014) Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci 17:46–55. https://doi.org/10.1038/nn.3597
Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343:227–235. https://doi.org/10.1007/s00441-010-1034-0
Schalper KA et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470–476. https://doi.org/10.1038/s41591-018-0339-5
Schatton T et al (2008) Identification of cells initiating human melanomas. Nature 451:345–349. https://doi.org/10.1038/nature06489
Schuster J et al (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861. https://doi.org/10.1093/neuonc/nou348
Schwartz RH (1985) T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 3:237–261. https://doi.org/10.1146/annurev.iy.03.040185.001321
Sebina I, Pepper M (2018) Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics. Curr Opin Immunol 51:46–54. https://doi.org/10.1016/j.coi.2018.02.001
Smith LM et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109. https://doi.org/10.1038/sj.bjc.6604437
Sobol RE et al (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164–167
Soling A, Rainov NG (2001) Dendritic cell therapy of primary brain tumors. Mol Med 7:659–667
Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159:4772–4780
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Tsai RK, Discher DE (2008) Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180:989–1003. https://doi.org/10.1083/jcb.200708043
Uyttenhove C et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274. https://doi.org/10.1038/nm934
Vakilian A, Khorramdelazad H, Heidari P, Sheikh Rezaei Z, Hassanshahi G (2017) CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int 103:1–7. https://doi.org/10.1016/j.neuint.2016.12.013
Vasco C et al (2013) Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. J Neurooncol 115:353–363. https://doi.org/10.1007/s11060-013-1236-x
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510. https://doi.org/10.1038/ni1582
Vom Berg J et al (2013) Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med 210:2803–2811. https://doi.org/10.1084/jem.20130678
Wainwright DA et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110–6121. https://doi.org/10.1158/1078-0432.Ccr-12-2130
Wainwright DA et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290–5301. https://doi.org/10.1158/1078-0432.Ccr-14-0514
Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M (2020) Immunotherapy in glioblastoma: current shortcomings and future perspectives. Cancers 12:751. https://doi.org/10.3390/cancers12030751
Wei J et al (2010) Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 16:461–473. https://doi.org/10.1158/1078-0432.Ccr-09-1983
Wei J et al (2011) Hypoxia potentiates glioma-mediated immunosuppression. PLoS ONE 6:e16195. https://doi.org/10.1371/journal.pone.0016195
Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069–1086. https://doi.org/10.1158/2159-8290.Cd-18-0367
Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E (1997) CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain cellular. Physiol Biochem 7:282–288. https://doi.org/10.1159/000154883
Weller M et al (2014) Assessment and prognostic significance of the epidermal growth factor receptor VIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 134:2437–2447. https://doi.org/10.1002/ijc.28576
Weller M et al (2017a) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/s1470-2045(17)30517-x
Weller M et al (2017b) European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/s1470-2045(17)30194-8
Wen PY et al (2019) A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 25:5799–5807. https://doi.org/10.1158/1078-0432.Ccr-19-0261
Willingham SB et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109:6662–6667. https://doi.org/10.1073/pnas.1121623109
Wirsching HG, Weiss T, Roth P, Weller M (2018) Basic principles of diagnosis and treatment of gliomas. Nervenarzt 89:692–698. https://doi.org/10.1007/s00115-018-0519-z
Wrann M et al (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. Embo j 6:1633–1636
Wu W et al (2010) Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 12:164–172. https://doi.org/10.1093/neuonc/nop019
Yadav A, Saini V, Arora S (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411:1570–1579. https://doi.org/10.1016/j.cca.2010.07.006
Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710
Ye XZ et al (2012) Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol 189:444–453. https://doi.org/10.4049/jimmunol.1103248
Yu JS et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979. https://doi.org/10.1158/0008-5472.Can-03-3505
Zeng J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349. https://doi.org/10.1016/j.ijrobp.2012.12.025
Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Yong VW (2012) A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 33:312–319. https://doi.org/10.1093/carcin/bgr289
Zhang M et al (2016) Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE 11:e0153550–e0153550. https://doi.org/10.1371/journal.pone.0153550
Zhang W et al (2020) Advances in anti-tumor treatments targeting the CD47/SIRPalpha axis. Front Immunol 11:18. https://doi.org/10.3389/fimmu.2020.00018
Zhu X, Fujita M, Snyder LA, Okada H (2011) Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 104(1):83–92. Epub 2010 Nov 30. PMID: 21116835, PMCID: PMC3068234. https://doi.org/10.1007/s11060-010-0473-5
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tay, A.SM.S., Black, K.L., Yu, J.S. (2023). The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. In: Rezaei, N., Hanaei, S. (eds) Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 1. Advances in Experimental Medicine and Biology, vol 1394. Springer, Cham. https://doi.org/10.1007/978-3-031-14732-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-14732-6_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14731-9
Online ISBN: 978-3-031-14732-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)